 |
인쇄하기
취소
|
Lucentis improves vision in patients with wet age-related macular degeneration
Korean scientists announced positive six-month data of Novatis's Lucentis (ranibizumab) from a local clinical study.
The study successfully reached its primary endpoints and reported unprecedented results in maintaining and/or improving vision for 13 patients with wet age-related macular degeneration (AMD). The trial results were presented at the Annual Meeting of the Korean Ophthalmological...
The study successfully reached its primary endpoints and reported unprecedented results in maintaining and/or improving vision for 13 patients with wet age-related macular degeneration (AMD). The trial results were presented at the Annual Meeting of the Korean Ophthalmological...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.